Lender Takes Control of GeoVax Board in $1M Rescue Loan
GOVX is trading near its 52-week low of $0.19 (2.5% above the low) on light trading volume (0.3× avg).
Summary
GeoVax signed a $1,000,000 unsecured revolving loan with Bowery Consulting Group on October 23 at 12% interest, maturing in 12 months, with every draw subject to the lender's approval. The price of that money is board control: five directors resigned the same day and three lender-nominated directors — Steven Brown, Tyler O'Brien and Manpreet Uppal — were seated, leaving a five-person board that serves only until the loan is repaid in full. This lands on a company whose last 10-Q showed $3.1 million of cash funding operations only into September 2026, and which is already fighting a Nasdaq delisting determination with an appeal hearing set for October 13, 2026. A $1 million facility that the lender can simply decline to advance is not a fix for that hole, and handing board seats to the creditor puts the lender ahead of equity in any restructuring. Shareholders vote October 27 on a reverse split and on issuing 11.4 million warrant shares tied to the August warrant inducement.
At the time of this announcement, GOVX was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.19 to $15.17. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: EQS.